Related Experiment Video
Updated: Jan 25, 2026

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis
Teclegiorgis Gebremariam1, Sondus Alkhazraji1, Clara Baldin1
1Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles (UCLA) Medical Center and St. John's Cardiovascular Research Center, Torrance, California, USA.
Abstract:
We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.
Insights
Isavuconazole and posaconazole show promise for preventing and treating pulmonary mucormycosis in mice. These antifungal therapies significantly improved survival and reduced fungal burden in infected, immunosuppressed rodents.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Pulmonary mucormycosis is a severe fungal infection with high mortality.
- Limited effective treatment options exist for mucormycosis, necessitating research into novel antifungal therapies.
Purpose of the Study:
- To evaluate the efficacy of isavuconazole, posaconazole, and voriconazole for treating pulmonary mucormycosis in an immunosuppressed murine model.
- To compare prophylactic and continuous treatment strategies for these antifungal agents.
Main Methods:
- Immunosuppressed mice infected with *Rhizopus delemar* were treated with prophylactic or continuous regimens of isavuconazole, posaconazole, or voriconazole.
- Survival rates and fungal burden in lung tissue were assessed to determine treatment efficacy.
Main Results:
- Prophylactic isavuconazole significantly improved survival and reduced fungal burden compared to placebo.
- Continuous therapy with isavuconazole and posaconazole, but not voriconazole, prolonged survival and lowered fungal burden.
- Isavuconazole demonstrated efficacy in both prophylactic and continuous treatment settings.
Conclusions:
- Isavuconazole and posaconazole are effective in treating pulmonary mucormycosis in mice, particularly in prophylactic settings.
- These findings support the clinical investigation of isavuconazole and posaconazole for mucormycosis treatment.
- Voriconazole showed limited efficacy in this murine model of pulmonary mucormycosis.
Related Concept Videos
Protecting Self-Esteem
Zones of Protection
Protective zones are defined by closed dashed lines, containing one or more components. A key characteristic of these zones is the strategic placement of...
Protection of Alcohols
Protection
It defines a protecting group as the masking agent to make the more reactive species inert to a given set of conditions. This concept is depicted via the illustration of liquid flow through different outlets in an assembly of pipes. The analogy helps to understand the role...
Radial System Protection
In a radial system with a fault downstream of the third breaker, ideally, only the third breaker will open, isolating the fault and interrupting the load connected beyond it. The second breaker has a longer delay setting,...
Line Protection with Impedance Relays
Under normal conditions, low load currents keep the measured...
Personal Protective Equipment

